Nuclastaml Injection 1 ml Substitute
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
by Others
Composition:
DENOSUMAB-60MG
Uses:
Osteoporosis, bone loss, giant cell tumour of the bone, high calcium levels.
Medicinal Benefits:
Nuclastaml Injection 1 ml belongs to a group of medicines called RANK ligand inhibitors used to treat osteoporosis in postmenopausal women and men who have an increased risk of fracture. Nuclastaml Injection 1 ml is also used to treat bone loss due to reduced hormone levels caused by surgery or due to treatment with medicines in patients with prostate cancer. It is also used to treat bone loss occurring due to long-term treatment with glucocorticoids in patients who are at an increased risk of fractures. Nuclastaml Injection 1 ml may also be used to reduce the risk of fractures in people with multiple myeloma, giant cell tumours of the bone and to treat high calcium levels caused due to cancer. Nuclastaml Injection 1 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. Thereby decreases bone breakdown, increases bone density, and strengthens the bone. Nuclastaml Injection 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slows the tumour growth. Nuclastaml Injection 1 ml helps treat high calcium levels by decreasing bone breakdown as the breakdown of the bones releases calcium. Nuclastaml Injection 1 ml makes the bones stronger and less likely to break.
Nuclastaml Injection 1 ml binds to a protein on RANK ligand on osteoclast (cells that cause bone breakdown) and inhibits their formation, functioning and survival. Thereby decreases bone breakdown, increases bone density, and strengthens the bone. Nuclastaml Injection 1 ml makes the bones stronger and less likely to break.
Osteonecrosis of the jaw (bone damage in the jaw) might be a side-effect of Nuclastaml Injection 1 ml. The risk increases in people taking Nuclastaml Injection 1 ml for longer durations. It might also occur upon discontinuation of the treatment. Maintain good dental hygiene and receive regular dental check-ups whilst on treatment with Nuclastaml Injection 1 ml. Inform your doctor if you have dental problems, gum disease, planned tooth extractions, cancer, if you smoke, or are taking bisphosphonates or corticosteroids.
Breakdown of bones releases calcium and causes hypercalcemia (high calcium levels in the blood). Nuclastaml Injection 1 ml helps treat high calcium levels by decreasing bone breakdown.
Unusual thigh bone fractures might occur whilst on treatment with Nuclastaml Injection 1 ml. Consult your doctor if you experience new or unusual pain in the thigh, hip, or groin.
Nuclastaml Injection 1 ml treats giant cell tumour of bone (GCTB) by blocking certain receptors in the tumour cells, thereby slows the tumour growth. Giant cell tumour of the bone is a non-cancerous tumour that typically grows at the ends of long bones.
Nuclastaml Injection 1 ml might cause skin infections. Consult your doctor immediately if you notice symptoms such as swollen skin, redness, cellulitis (hot and tender skin), commonly in the lower leg with feverish symptoms.